The Globe and Mail reports in its Wednesday, Sept. 27, edition that Canaccord Genuity analyst Katie Lachapelle is sticking with her "buy" call on Cameco. The Globe's David Leeder writes that Ms. Lachapelle boosted her share target by $4 to $60. Analysts on average target the shares at $15.15. The Globe reports that the Canaccord stockpicker says she remains "fundamentally bullish" on the uranium market, believing it "remains in a structural deficit, and with secondary supplies on the decline and inventory levels near recent lows (or immobile)." In a report released Tuesday, she increased her demand forecast, expecting total nuclear capacity to grow at a annual growth rate of 3.6 per cent through 2030 and 3.2 per cent through 2035. This equates to a 30-per-cent increase in annual uranium demand through 2030 and 46 per cent through 2035. This growth is principally driven by new reactor builds in China/India but also supported by life extensions in the West. Conservatively, our forecast does not, at this point, include the deployment of small modular reactors." The Globe reported on Feb. 13 that Ms. Lachapelle had reaffirmed her "buy" recommendation for Cameco when it could be had for $33.78.